文献速递中枢神经肿瘤放疗放疗物理与技术

放化疗期间ADC动态变化预测胶质母细胞瘤空间复发

Temporal Apparent Diffusion Coefficient Changes During Chemoradiation: An Imaging Biomarker for Tumor Response Monitoring and Spatial Recurrence Prediction in Glioblastoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-03-26

这项前瞻性观察性序列影像研究纳入80例胶质母细胞瘤患者,在放疗计划时、第10次、第20次分次及6周放化疗结束后1个月行扩散加权成像。复发区域与GTV交集为抵抗-GTV,非交集为敏感-GTV;抵抗-GTV从放疗开始ADC变化即小于敏感-GTV,第10次分次时ADC变化较小是GTV失败的独立预测因素。

要点

  • 抵抗-GTV与敏感-GTV基线ADC相似,但从放疗开始出现显著差异。
  • 第10次分次ADC变化:抵抗-GTV +2.5% vs 敏感-GTV +15.1%(P < .001)。
  • 第10次分次ADC变化较小是GTV失败的独立预测因素(OR 0.95,P = .005)。

核心结论

  • ADC动态变化是有前景的影像生物标志物,可用于治疗反应和空间复发预测,并可能为MRI引导的生物自适应放疗临床试验提供靶点。

研究设计与样本

  • 前瞻性观察性序列影像研究,纳入80例胶质母细胞瘤患者,在放疗计划时(基线,第0次分次)、第10次分次、第20次分次及6周放化疗结束后1个月行扩散加权成像。
  • 复发在最早显示进展的MRI上勾画,GTV与复发的交集为抵抗-GTV,非交集为敏感-GTV,比较两区域ADC值及相对第0次分次的百分比变化。

主要发现

  • 基线中位绝对ADC值抵抗-GTV为0.94 μm2/ms(IQR 0.84-1.08),敏感-GTV为0.93 μm2/ms(IQR 0.87-1.13),两者相似(P = .193)。
  • 第10次分次时中位ADC较基线变化:抵抗-GTV +2.5% vs 敏感-GTV +15.1%(P < .001)。
  • 第20次分次时中位ADC较基线变化:抵抗-GTV +8.1% vs 敏感-GTV +23.1%(P < .001)。
  • 6周放化疗结束后1个月中位ADC较基线变化:抵抗-GTV +21.2% vs 敏感-GTV +36.4%(P < .001)。
  • 校正O6-甲基鸟嘌呤DNA甲基转移酶启动子甲基化和手术切除范围后,第10次分次(OR 0.95,P = .005)和第20次分次(OR 0.95,P = .010)较小的ADC变化是GTV失败风险增加的独立预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Apparent diffusion coefficient (ADC) from diffusion-weighted imaging has been shown to detect early treatment response in glioblastoma. This prospective observational serial imaging study aimed to compare ADC changes in gross tumor volume (GTV) regions that developed recurrence versus those that remained recurrence-free. METHODS AND MATERIALS: Patients with glioblastoma underwent diffusion-weighted imaging at radiation planning (baseline, fraction 0), fraction 10, fraction 20, and 1 month after completing a 6-week course of chemoradiation. Recurrence was contoured at the earliest magnetic resonance imaging showing progression. The intersection of the GTV and recurrence was labeled resistant-GTV, whereas nonintersecting GTV was labeled sensitive-GTV. ADC values and percentage changes from fraction 0 were compared between these regions. RESULTS: Eighty patients were analyzed. Median absolute ADC values for resistant (0.94 μm2/ms; IQR, 0.84-1.08) and sensitive-GTV (0.93 μm2/ms; IQR, 0.87-1.13) were similar at baseline (P = .193), but statistically significant differences were observed from the start of radiation therapy. Median ADC changes from baseline for resistant- and sensitive-GTV were +2.5% versus +15.1% at fraction 10 (P < .001), +8.1% versus +23.1% at fraction 20 (P < .001), and +21.2% versus +36.4% at 1 month after completing a 6-week course of chemoradiation (P <.001), respectively. Smaller ADC changes at fraction 10 (odds ratio, 0.95; P = .005) and fraction 20 (odds ratio, 0.95; P = .010) were independent predictors of increased risk of GTV failure, adjusting for O6-methylguanine DNA methyltransferase promoter methylation and extent of surgical resection. CONCLUSIONS: Temporal ADC changes are promising imaging biomarkers for treatment response and spatial recurrence prediction and may provide a target for magnetic resonance imaging-guided biologically adapted radiation clinical trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Moore-Palhares D, Lawrence LSP, Myrehaug S, et al. Temporal Apparent Diffusion Coefficient Changes During Chemoradiation: An Imaging Biomarker for Tumor Response Monitoring and Spatial Recurrence Prediction in Glioblastoma. Int J Radiat Oncol Biol Phys. 2025. PMID: 40154848. doi:10.1016/j.ijrobp.2025.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。